{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:05:22Z","timestamp":1759341922387},"reference-count":36,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b16-00972","type":"journal-article","created":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T22:07:43Z","timestamp":1493590063000},"page":"681-686","source":"Crossref","is-referenced-by-count":4,"title":["Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy"],"prefix":"10.1248","volume":"40","author":[{"given":"Hiroyoshi","family":"Koide","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Science, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shiga University of Medical Science Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Science, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurie","family":"Katsube","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Science, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Minegaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Science, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uzu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shiga University of Medical Science Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ya","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shiga University of Medical Science Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohshi","family":"Nishiguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Science, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shiga University of Medical Science Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Choi HK, Mount DB, Reginato AM, American College of Physicians, American Physiological Society. Pathogenesis of gout. <i>Ann. Intern. Med.<\/i>, <b>143<\/b>, 499\u2013516 (2005).","DOI":"10.7326\/0003-4819-143-7-200510040-00009"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. <i>Arthritis Rheum.<\/i>, <b>51<\/b>, 321\u2013325 (2004).","DOI":"10.1002\/art.20405"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. <i>Am. J. Med.<\/i>, <b>120<\/b>, 442\u2013447 (2007).","DOI":"10.1016\/j.amjmed.2006.06.040"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. <i>Cochrane Database Syst. Rev.<\/i>, <b>11<\/b>, CD008653 (2012).","DOI":"10.1002\/14651858.CD008653.pub2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. <i>Am. J. Med.<\/i>, <b>76<\/b>, 47\u201356 (1984).","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"6","unstructured":"6) Saji M. A study of serum oxipurinol concentration and renal function in patients administered allopurinol. <i>Nippon Jinzo Gakkai Shi<\/i>, <b>38<\/b>, 640\u2013650 (1996)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Mukoyoshi M, Nishimura S, Hoshide S, Umeda S, Kanou M, Taniguchi K, Muroga H. <i>In vitro<\/i> drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. <i>Xenobiotica<\/i>, <b>38<\/b>, 496\u2013510 (2008).","DOI":"10.1080\/00498250801956350"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. <i>J. Clin. Pharmacol.<\/i>, <b>51<\/b>, 189\u2013201 (2011).","DOI":"10.1177\/0091270010365549"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. <i>Arthritis Res. Ther.<\/i>, <b>12<\/b>, R63 (2010).","DOI":"10.1186\/ar2978"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, Yano Y, Morita SY, Terada T. Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment. <i>Pharmacology<\/i>, <b>96<\/b>, 90\u201398 (2015).","DOI":"10.1159\/000434633"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. <i>Clin. Rheumatol.<\/i>, <b>33<\/b>, 1643\u20131648 (2014).","DOI":"10.1007\/s10067-014-2745-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Altan A, Shiozawa A, Bancroft T, Singh JA. A real-world study of switching from allopurinol to febuxostat in a health plan database. <i>J. Clin. Rheumatol.<\/i>, <b>21<\/b>, 411\u2013418 (2015).","DOI":"10.1097\/RHU.0000000000000322"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. <i>N. Engl. J. Med.<\/i>, <b>353<\/b>, 2450\u20132461 (2005).","DOI":"10.1056\/NEJMoa050373"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients \u226565 years of age. <i>BMC Geriatr.<\/i>, <b>12<\/b>, 11 (2012).","DOI":"10.1186\/1471-2318-12-11"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, Kamatani N. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. <i>Adv. Exp. Med. Biol.<\/i>, <b>431<\/b>, 13\u201318 (1998).","DOI":"10.1007\/978-1-4615-5381-6_3"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. <i>Clin. Pharmacokinet.<\/i>, <b>45<\/b>, 821\u2013841 (2006).","DOI":"10.2165\/00003088-200645080-00005"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. <i>Br. J. Clin. Pharmacol.<\/i>, <b>65<\/b>, 355\u2013363 (2008).","DOI":"10.1111\/j.1365-2125.2007.03016.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. <i>J. Clin. Pharmacol.<\/i>, <b>48<\/b>, 1014\u20131024 (2008).","DOI":"10.1177\/0091270008322035"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. <i>J. Clin. Pharmacol.<\/i>, <b>46<\/b>, 88\u2013102 (2006).","DOI":"10.1177\/0091270005282634"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T. PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. <i>Nucleosides Nucleotides Nucleic Acids<\/i>, <b>23<\/b>, 1117\u20131118 (2004).","DOI":"10.1081\/NCN-200027377"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>42<\/b>, 333\u2013335 (1992).","DOI":"10.1007\/BF00266358"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Reyes AJ. Cardiovascular drugs and serum uric acid. <i>Cardiovasc. Drugs Ther.<\/i>, <b>17<\/b>, 397\u2013414 (2003).","DOI":"10.1023\/B:CARD.0000015855.02485.e3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. <i>Nephron<\/i>, <b>59<\/b>, 364\u2013368 (1991).","DOI":"10.1159\/000186593"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. <i>Clin. Pharmacol.<\/i>, <b>6<\/b>, 79\u201386 (2014).","DOI":"10.2147\/CPAA.S61462"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Zhang M, Di X, Xu L, Xu J, Yang Y, Jiang N, Song L, Xu X. Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. <i>Exp. Ther. Med.<\/i>, <b>7<\/b>, 393\u2013396 (2014).","DOI":"10.3892\/etm.2013.1414"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Xu S, Liu X, Ming J, Chen S, Wang Y, Liu X, Liu H, Peng Y, Wang J, Lin J, Ji H, Liu B, Lu Y, Liu P, Zhang Y, Ji Q. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. <i>Int. J. Rheum. Dis.<\/i>, <b>18<\/b>, 669\u2013678 (2015).","DOI":"10.1111\/1756-185X.12648"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liot\u00e9 F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Piment\u00e3o J, Punzi L, Roddy E, Uhlig T, Zimmermann-G\u00f2rska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Ann. Rheum. Dis.<\/i>, <b>65<\/b>, 1312\u20131324 (2006).","DOI":"10.1136\/ard.2006.055269"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. <i>N. Engl. J. Med.<\/i>, <b>353<\/b>, 2450\u20132461 (2005).","DOI":"10.1056\/NEJMoa050373"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. <i>J. Clin. Rheumatol.<\/i>, <b>17<\/b> (Suppl. 2), S13\u2013S18 (2011).","DOI":"10.1097\/RHU.0b013e31821d36cc"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. <i>Clin. Pharmacokinet.<\/i>, <b>46<\/b>, 623\u2013644 (2007).","DOI":"10.2165\/00003088-200746080-00001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Mizuno T, Hayashi T, Hikosaka S, Shimabukuro Y, Murase M, Takahashi K, Hayashi H, Yuzawa Y, Nagamatsu T, Yamada S. Efficacy and safety of febuxostat in elderly female patients. <i>Clin. Interv. Aging<\/i>, <b>9<\/b>, 1489\u20131493 (2014).","DOI":"10.2147\/CIA.S70855"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ant\u00f3n FM, Garc\u00eda Puig J, Ramos T, Gonz\u00e1lez P, Ord\u00e1s J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. <i>Metabolism<\/i>, <b>35<\/b>, 343\u2013348 (1986).","DOI":"10.1016\/0026-0495(86)90152-6"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Hosoya T, Ohno I. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. <i>J. Clin. Rheumatol.<\/i>, <b>17<\/b> (Suppl. 2), S27\u2013S34 (2011).","DOI":"10.1097\/RHU.0b013e31821d36f2"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Lim DH, Oh JS, Ahn SM, Hong S, Kim YG, Lee CK, Choi SW, Yoo B. Febuxostat in hyperuricemic patients with advanced CKD. <i>Am. J. Kidney Dis.<\/i>, <b>68<\/b>, 819\u2013821 (2016).","DOI":"10.1053\/j.ajkd.2016.07.001"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Wang M, Jiang X, Wu W, Zhang D. A meta-analysis of alcohol consumption and the risk of gout. <i>Clin. Rheumatol.<\/i>, <b>32<\/b>, 1641\u20131648 (2013).","DOI":"10.1007\/s10067-013-2319-y"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y, Chiba T, Tadokoro S, Takada Y, Oikawa Y, Inoue H, Suzuki K, Okada R, Nishiyama J, Domoto H, Watanabe S, Fujita M, Morimoto Y, Naito M, Nishio K, Hishida A, Wakai K, Asai Y, Niwa K, Kamakura K, Nonoyama S, Sakurai Y, Hosoya T, Kanai Y, Suzuki H, Hamajima N, Shinomiya N. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. <i>Sci. Transl. Med.<\/i>, <b>1<\/b>, 5ra11 (2009).","DOI":"10.1126\/scitranslmed.3000237"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/5\/40_b16-00972\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T15:34:00Z","timestamp":1569166440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/5\/40_b16-00972\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00972","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}